Literature DB >> 2253669

Variation of benzbromarone elimination in man--a population study.

I Walter-Sack1, U Gresser, M Adjan, I Kamilli, A Ittensohn, J X de Vries, E Weber, N Zöllner.   

Abstract

The plasma benzbromarone concentration-time profile in a healthy subject who retained the compound much longer than other individuals is described. The data suggested that determination of the 24 h plasma concentration of the parent drug after a single oral dose of 100 mg benzbromarone would be an appropriate procedure to determine the elimination phenotype. Based on this procedure, 148 of 153 healthy individuals (97%) in a population study were found to eliminate benzbromarone rapidly. In one subject the 24 h benzbromarone plasma concentration was very similar to that observed in the individual who had been more fully characterized. Four participants gave intermediate results. The data are compatible with a bimodal or trimodal distribution of different benzbromarone elimination phenotypes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253669     DOI: 10.1007/bf00280054

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Deficient benzbromarone elimination: a familial disorder?

Authors:  N Zöllner; U Gresser; I Walter-Sack
Journal:  Klin Wochenschr       Date:  1990-01-19

2.  Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

Authors:  I Walter-Sack; M Eichelbaum; J X de Vries; E Weber
Journal:  Klin Wochenschr       Date:  1988-11-01

3.  [Effect of benzbromaronum on the renal uric acid excretion in healthy persons].

Authors:  N Zöllner; W Dofel; W Gröbner
Journal:  Klin Wochenschr       Date:  1970-04-01

4.  [Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].

Authors:  H J Dengler; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

Review 5.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 6.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

8.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

9.  Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; M Kohlmeier; E Weber
Journal:  Klin Wochenschr       Date:  1988-02-15

10.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

View more
  3 in total

1.  Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite.

Authors:  J X de Vries; I Walter-Sack; A Ittensohn; E Weber; H Empl; U Gresser; N Zöllner
Journal:  Clin Investig       Date:  1993-11

3.  Refractory gout attack.

Authors:  Simone Fargetti; Claudia Goldenstein-Schainberg; Andressa Silva Abreu; Ricardo Fuller
Journal:  Case Rep Med       Date:  2012-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.